Ozagrel

Ozagrel (INN) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.[1]

Ozagrel
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • (2E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]acrylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.122.039
Chemical and physical data
FormulaC13H12N2O2
Molar mass228.251 g·mol−1
3D model (JSmol)
SMILES
  • C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
InChI
  • InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+ N
  • Key:SHZKQBHERIJWAO-AATRIKPKSA-N N
 NY (what is this?)  (verify)

References

  1. Loo MH, Egan D, Vaughan ED, Marion D, Felsen D, Weisman S (March 1987). "The effect of the thromboxane A2 synthesis inhibitor OKY-046 on renal function in rabbits following release of unilateral ureteral obstruction". J. Urol. 137 (3): 571–6. doi:10.1016/s0022-5347(17)44108-5. PMID 3820396.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.